This alliance leverages the companies’ strengths as two of the world’s leading pharmaceutical companies, combining Boehringer Ingelheim’s solid track record of research-driven innovation and Lilly’s innovative research, experience and pioneering history in diabetes.
Clinical audit: Management of heart failure with reduced ejection fraction
Review your management of patients with HFrEF (heart failure with reduced ejection fraction) in this clinical audit, and update their treatment to be in line with latest recommendations including the "four pillars" approach.
Heart failure in general practice: Putting latest recommendations into practice advanced course
The new 2022 Australian consensus statement on heart failure has brought significant changes to how general practitioners should manage this condition.
In this advanced course you will understand how to classify HF into heart failure with reduced ejection fraction (HFrEF), heart failure with mildly reduced ejection fraction (HFmrEF) or heart failure with preserved ejection fraction (HFpEF).
On-demand webinar: Exploring diagnosis and management of heart failure in preserved ejection fraction
Hosted by Dr Shane Nanayakkara (interventional, structural and heart failure cardiologist) and A/Prof Ralph Audehm (General Practitioner), this on-demand webinar describes the diagnostic process in HFpEF and explores differences between the management of HFpEF and heart failure with reduced ejection fraction (HFrEF).
HFpEF 2hr module: Diagnosis and management of heart failure in preserved ejection fraction in primary care
This 2-hour educational activity explores the diagnosis and management of HFpEF in general practice, with a focus on updated management recommendations from the 2022 Australian Consensus Statement on Heart Failure.
Updated management of HFrEF in general practice
[Expert video | Duration: 11:06] With new Australian consensus recommendations and available therapies for heart failure with reduced ejection fraction (HFrEF), GPs now have further options for optimising management of their HFrEF patients. Listen to Dr Chee Khoo discuss the updated recommendations and its implications for clinical practice, in both current and newly diagnosed patients.
